Trial
NCT02928029
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Multiple Myeloma
Intervention
Radium-223 dichloride (Xofigo, BAY88-8223)
Why stopped
Due to the changes of standard of care and the slow recruitment of participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-26